1.31

0.76% -0.01

Pulmatrix Inc (PULM)

Overview News Price History Financials Discussions Forecast Stock Split

Pulmatrix Inc stock is traded at $1.31, with a volume of 25,190. It is down -0.76% in the last 24 hours and down -30.69% over the past month. Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Previous Close:

$1.32

Open:

$1.35

24h Volume:

25,190

Relative Volume:

0.58

Market Cap:

$4.78M

Revenue:

$3,000

Net Income/Loss:

$-5.16M

P/E Ratio:

-0.9269

EPS:

-1.4133

Net Cash Flow:

$-5.43M

1W Performance:

-13.25%

1M Performance:

-30.69%

6M Performance:

-73.10%

1Y Performance:

-78.38%

1-Day Range:

$1.28

$1.3899

1-Week Range:

$1.20

$1.47

52-Week Range:

$1.20

$9.37

Pulmatrix Inc Stock (PULM) Company Profile

Name

Pulmatrix Inc

Sector

Healthcare (1118)

Industry

Biotechnology (624)

Phone

(888) 355-4440

Address

945 CONCORD STREET, FRAMINGHAM, MA

Employee

Twitter

@pulmatrix_inc

Next Earnings Date

2024-11-07

Latest SEC Filings

PULM's Discussions on Twitter

Compare PULM vs VRTX, REGN, ARGX, ALNY, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PULM Pulmatrix Inc	1.31	4.78M	3,000	-5.16M	-5.43M	-1.4133
VRTX Vertex Pharmaceuticals Inc	438.71	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	761.85	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	746.42	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	318.85	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	162.43	35.01B	606.42M	-1.28B	-997.58M	-6.403

Pulmatrix Inc Stock (PULM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-09-18	Initiated	H.C. Wainwright	Buy

Pulmatrix Inc Stock (PULM) Latest News

Apr 01, 2026

If You Invested $1,000 in Pulmatrix (PULM) - Stock Titan

Apr 01, 2026

Mar 31, 2026

FOMO Trade: Will Pulmatrix Inc benefit from current market trendsQuarterly Trade Review & Consistent Income Trade Recommendations - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

FRA:2PU PB Ratio: 1.34 — 15% Above Median - GuruFocus

Mar 30, 2026

Mar 29, 2026

Pulmatrix and Eos SENOLYTIX Announce $19 Million Merger to Advance Mitochondrial Therapies - Global Legal Chronicle

Mar 29, 2026

Mar 28, 2026

Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN

Mar 28, 2026

Ideas Watch: Is Pulmatrix Inc in a consolidation phaseQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn

Mar 28, 2026

Pulmatrix and Eos SENOLYTIX Announce $19M Merger to Advance AI-Driven Mitochondrial Therapies for Sarcopenia and Aging-Related Diseases 1 - Minichart

Mar 28, 2026

Mar 27, 2026

Pulmatrix to Merge With Eos SENOLYTIX, Rebrand on Nasdaq - tipranks.com

Mar 27, 2026

Pulmatrix to Merge With Eos SENOLYTIX; Raises $1M Preferred, Eos Secures Up to $18M - TradingView

Mar 27, 2026

Pulmatrix (PULM) plans reverse merger with Eos SENOLYTIX, legacy holders keep ~6% - Stock Titan

Mar 27, 2026

Haynes Boone Advises on Pulmatrix–Eos Merger and $19MM Financing - ABF Journal

Mar 27, 2026

Mar 26, 2026

Pulmatrix to acquire Eos SENOLYTIX in $19M anti-aging deal - Investing.com India

Mar 26, 2026

Pulmatrix and Eos SENOLYTIX Unite to Pioneer Anti-Aging Therapies Targeting Mitochondrial Health - Beijing Times

Mar 26, 2026

Deal Watch: Pulmatrix Finds New Merger Partner In Eos Senolytix - Citeline News & Insights

Mar 26, 2026

Eos SENOLYTIX, Inc. agreed to acquire Pulmatrix, Inc. in a reverse merger transaction. - MarketScreener

Mar 26, 2026

Aug Fed Impact: Is Pulmatrix Inc forming higher highs and higher lows2026 Market Mood & Weekly Consistent Profit Watchlists - baoquankhu1.vn

Mar 26, 2026

Pulmatrix: Merger With Eos SENOLYTIX To Advance Mitochondrial Therapies - Pulse 2.0

Mar 26, 2026

Pulmatrix To Merge with Eos SENOLYTIX - citybiz

Mar 26, 2026

Pulmatrix (PULM) to Acquire Eos Senolytix in Strategic Merger - GuruFocus

Mar 26, 2026

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan - PR Newswire

Mar 26, 2026

Mar 25, 2026

Pulmatrix, Inc. announced that it expects to receive $1 million in funding - MarketScreener

Mar 25, 2026

Mar 21, 2026

Buyout Rumor: Can Pulmatrix Inc grow without dilution2026 Closing Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn

Mar 21, 2026

Pulmatrix (NASDAQ:PULM) Stock Crosses Above Fifty Day Moving Average – Here’s Why - Defense World

Mar 21, 2026

Aug Catalysts: What are the analyst revisions for Vroom IncIs Pulmatrix Inc stock a good investment in YEARTrade Exit Report & Expert Verified Stock Movement Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 10, 2026

Risk Off: What is the earnings history of Pulmatrix IncWeekly Stock Report & Weekly High Conviction Ideas - baoquankhu1.vn

Mar 10, 2026

Mar 07, 2026

Why Pulmatrix Inc. stock is a value investor pickJuly 2025 Price Swings & Daily Growth Stock Investment Tips - Naître et grandir

Mar 07, 2026

Mar 04, 2026

Surprises Report: Will Pulmatrix Inc benefit from rising consumer demandShare Buyback & Capital Efficient Trade Techniques - baoquankhu1.vn

Mar 04, 2026